Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

Published:2015-03-02 Issue:9 Volume:6 Page:6597-6610
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Cani Alice¹,Simioni Carolina¹,Martelli Alberto M.²,Zauli Giorgio³,Tabellini Giovanna⁴,Ultimo Simona¹,McCubrey James A.⁵,Capitani Silvano¹⁶,Neri Luca M.¹

Affiliation:

1. Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy

2. Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy

3. Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”, Trieste, Italy

4. Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

5. Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA

6. LTTA Center, University of Ferrara, Ferrara, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome;Cancer Cell International;2024-07-04

2. MAPK/ERK and PI3K/AKT signaling pathways are activated in adolescent and adult acute lymphoblastic leukemia;Cancer Reports;2023-10-22

3. Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis;Scientific Reports;2023-08-02

4. In the Pipeline—Emerging Therapy for ALL;Pathogenesis and Treatment of Leukemia;2023

5. The Complexity of the Tumor Microenvironment and Its Role in Acute Lymphoblastic Leukemia: Implications for Therapies;Frontiers in Oncology;2021-05-05